{"filings":[{"id":68041,"accession_number":"0001437749-26-016718","cik":1285819,"company_name":"OMEROS CORP","ticker":"OMER","form_type":"8-K","filed_at":"2026-05-13T20:06:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Omeros Q1 net income $56.1M on $73.1M non-cash gain; YARTEMLEA net sales $9.9M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP net income $56.1M ($0.78/share) vs. net loss $33.5M ($0.58) in Q1 2025; includes $73.1M non-cash gain on embedded derivatives.","Non-GAAP adjusted net loss $17.1M ($0.24/share); total operating expenses fell 22% to $27.3M.","YARTEMLEA launch in Jan 2026: gross sales $11.1M, net sales $9.9M; CMS assigned J-code (eff. July 1) and recommended NTAP (eff. Oct 1).","Cash and short-term investments $135.3M; repaid $17.1M 2026 Notes; only $70.8M 2029 Notes remain (mature June 2029).","Repurchased 0.4M shares at avg $11.70 for $4.2M; MAA for YARTEMLEA under EMA review with decision expected mid-2026."],"consensus_eps_estimate":null,"consensus_eps_actual":0.62,"consensus_revenue_estimate":null,"consensus_revenue_actual":9893000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":797576345.5519421,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":102343,"accession_number":"0001437749-26-010634","cik":1285819,"company_name":"OMEROS CORP","ticker":"OMER","form_type":"8-K","filed_at":"2026-03-31T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Omeros posts Q4 net income of $86.5M; YARTEMLEA approved, zaltenibart deal closed","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2025 net income $86.5M ($1.22/diluted EPS) vs. net loss $31.4M ($0.54) in Q4 2024; full-year net loss narrowed to $3.4M ($0.05) from $156.8M ($2.70).","Closed zaltenibart deal with Novo Nordisk Nov 2025, receiving $240M upfront; repaid $67.1M term loan and $17.1M convertible notes.","FDA approved YARTEMLEA (narsoplimab) for TA-TMA Dec 2025; commercial launch began Jan 2026.","Q4 OMIDRIA royalties $9.2M on $30.7M net sales vs. $10.1M on $33.6M in prior year.","Operating expenses fell to $122.8M in FY25 from $167.0M in FY24, down $44.2M."],"consensus_eps_estimate":-0.3264,"consensus_eps_actual":0.62,"consensus_revenue_estimate":null,"consensus_revenue_actual":9893000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":797576345.5519421,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":102342,"accession_number":"0001437749-26-000820","cik":1285819,"company_name":"OMEROS CORP","ticker":"OMER","form_type":"8-K","filed_at":"2026-01-07T23:59:59+00:00","items":["2.02"],"status":"ready","headline":"Omeros reports preliminary cash and short-term investments of $171.5M at year-end 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Preliminary unaudited cash and short-term investments of $171.5M as of Dec 31, 2025.","Figure is preliminary and subject to completion of customary closing procedures.","Disclosed during investor conference call on January 7, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":797576345.5519421,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118622,"accession_number":"0001437749-25-038758","cik":1285819,"company_name":"OMEROS CORP","ticker":"OMER","form_type":"8-K","filed_at":"2025-12-29T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"FDA approves Omeros' YARTEMLEA as first therapy for TA-TMA; launch set for Jan 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["YARTEMLEA (narsoplimab-wuug) approved for adults and children ≥2 years with hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA).","Pivotal trial CR rate 61%, EAP CR rate 68%; 100-day survival 73% and 74% respectively; all patients high-risk.","No Boxed Warning or REMS; most common adverse reactions (≥20%) include viral infections, sepsis, hemorrhage, diarrhea, vomiting, nausea, neutropenia, pyrexia, fatigue, hypokalemia.","U.S. launch planned for January 2026; dedicated ICD-10 and procedure codes in place; YARTEMLEAssist patient support program expected in Q1 2026.","Marketing authorization application under EMA review with decision expected mid-2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":797576345.5519421,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118621,"accession_number":"0001437749-25-036507","cik":1285819,"company_name":"OMEROS CORP","ticker":"OMER","form_type":"8-K","filed_at":"2025-12-01T23:59:59+00:00","items":["1.02","2.01","9.01"],"status":"ready","headline":"Omeros closes zaltenibart sale to Novo Nordisk for $240M upfront; repays debt, launches $100M buyback","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Closed sale of zaltenibart to Novo Nordisk for $240M upfront; eligible for up to $2.1B in milestones plus tiered royalties on net sales.","Used $72.6M of proceeds to repay $67.1M term loan, prepayment premium, interest; Credit Agreement terminated.","Board authorized up to $100M share repurchase program for common stock with indefinite term.","Remaining cash expected to fund >12 months of operations, including narsoplimab launch for TA-TMA.","Pro forma financials show net income of $124.4M for FY2024 and net loss of $69.9M for 9M2025 after asset sale adjustments."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.95,"calibrated_materiality_score":0.95,"market_cap_usd":797576345.5519421,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118620,"accession_number":"0001437749-25-034824","cik":1285819,"company_name":"OMEROS CORP","ticker":"OMER","form_type":"8-K","filed_at":"2025-11-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Omeros Q3 net loss narrows; Novo Nordisk deal for zaltenibart up to $2.1B","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Q3 net loss $30.9M ($0.47/sh) vs $32.2M ($0.56/sh) a year ago; adjusted net loss $22.1M ($0.34/sh).","Entered up to $2.1B asset purchase/license deal with Novo Nordisk for zaltenibart; $240M upfront at Q4 2025 close.","Cash $36.1M at Sep 30; Q3 cash burn $22M ex-financing; raised $20.3M from Polar and $9M from ATM in Q3.","PDUFA date for narsoplimab in TA-TMA extended to Dec 26, 2025; commercial launch team ready with brand YARTEMLEA.","OMIDRIA royalties $9.2M in Q3 on net sales of $30.5M; operating expenses fell to $26.4M from $35.4M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":797576345.5519421,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118619,"accession_number":"0001437749-25-030968","cik":1285819,"company_name":"OMEROS CORP","ticker":"OMER","form_type":"8-K","filed_at":"2025-10-15T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Omeros sells global rights to zaltenibart to Novo Nordisk for up to $2.1B","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Upfront $240M cash plus near-term milestones total $340M; up to $2.1B including development & sales milestones plus tiered royalties.","Novo Nordisk gains exclusive global rights to develop and commercialize MASP-3 inhibitor zaltenibart in all indications.","Omeros will use part of upfront to repay $67.1M term loan; remaining funds support narsoplimab approval and preclinical pipeline.","Transaction expected to close Q4 2025, subject to HSR clearance and customary conditions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.95,"calibrated_materiality_score":0.95,"market_cap_usd":797576345.5519421,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":135105,"accession_number":"0001437749-25-026931","cik":1285819,"company_name":"OMEROS CORP","ticker":"OMER","form_type":"8-K","filed_at":"2025-08-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Omeros Q2 net loss narrows to $25.4M; narsoplimab PDUFA extended to Dec 2025; debt reduced by $80M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $25.4M ($0.43/sh) vs $56.0M ($0.97/sh) a year ago; cash, short-term investments $28.7M at June 30.","Post-quarter: raised $20.6M net from Polar Asset Management (5.37M shares at $4.10, 14% premium) plus $2.1M from ATM.","Narsoplimab BLA PDUFA date extended to Dec 26, 2025; FDA expects labeling talks by Oct. EMA MAA validated, opinion mid-2026.","Exchanged $70.8M of 2026 Notes for 2029 Notes; remaining 2026 Notes reduced to $17.1M; avoided $20M prepayment on term debt.","In talks for potential asset deal with multi-billion total value; upfront cash would repay $67.1M term loan and $17.1M notes."],"consensus_eps_estimate":-0.4906,"consensus_eps_actual":-1.01,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":797576345.5519421,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":135104,"accession_number":"0001104659-25-070554","cik":1285819,"company_name":"OMEROS CORP","ticker":"OMER","form_type":"8-K","filed_at":"2025-07-25T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Omeros prices $22M offering, discloses advanced partnership talks, narsoplimab PDUFA now Dec 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sold 5,365,853 shares at $4.10 each to Polar Asset Management; net proceeds ~$20.3M; expected close July 28.","Narsoplimab BLA PDUFA date extended from Sep 25, 2025 to Dec 26, 2025; labeling discussions planned by Oct 2025.","Advanced partnership discussion: potential multi-billion transaction value excl. royalties; upfront would repay $67.1M term loan and $17.1M notes.","Cash and equivalents $26.0M as of July 18; 61.8M shares outstanding.","PDE7 inhibitor program: preclinical studies for cocaine use disorder completed; FDA requests more preclinical info."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":797576345.5519421,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":135103,"accession_number":"0001437749-25-021959","cik":1285819,"company_name":"OMEROS CORP","ticker":"OMER","form_type":"8-K","filed_at":"2025-07-02T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Omeros shareholders elect directors, approve say-on-pay, ratify Ernst & Young","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Arnold C. Hanish elected Class I director with 16,033,755 for, 1,245,397 against.","Rajiv Shah, M.D. elected Class I director with 16,198,053 for, 946,241 against.","Advisory say-on-pay approved: 15,086,368 for, 1,856,643 against, 615,511 abstain.","Ernst & Young ratified as auditor for FY25: 41,204,073 for, 1,237,033 against.","Total shares represented at meeting: 42,725,983 (72.92% of outstanding)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":797576345.5519421,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":152078,"accession_number":"0001437749-25-017426","cik":1285819,"company_name":"OMEROS CORP","ticker":"OMER","form_type":"8-K/A","filed_at":"2025-05-16T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"Omeros files 8-K/A to correct omitted table in Second Supplemental Indenture","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Amendment filed solely to replace Exhibit 4.2 with corrected version including missing table.","Second Supplemental Indenture dated May 14, 2025 with Computershare Trust Company as trustee.","No other changes made to the original May 15, 2025 Current Report or to Exhibit 4.2.","Error stemmed from processing issue with embedded table; financial terms unaffected."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.05,"calibrated_materiality_score":0.05,"market_cap_usd":797576345.5519421,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":152080,"accession_number":"0001437749-25-017211","cik":1285819,"company_name":"OMEROS CORP","ticker":"OMER","form_type":"8-K","filed_at":"2025-05-15T23:59:59+00:00","items":["1.01","2.02","2.03","3.02","8.01","9.01"],"status":"ready","headline":"Omeros Q1 net loss $0.58/sh; swaps $70.8M of 2026 notes for 2029 notes at 9.5%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $33.5M ($0.58/diluted) vs $37.2M ($0.63) a year ago; OMIDRIA royalties $6.7M on sales of $22.3M.","Cash and short-term investments $52.4M at Mar 31, 2025, down $37.7M from Dec 31, 2024.","Exchanged $70.8M of 5.25% 2026 notes for new 9.50% 2029 notes; additionally $10M notes converting to equity.","Outstanding 2026 notes reduced to ~$17.1M; avoids $20M term loan prepayment plus $1M premium due Nov 2025.","FDA accepted BLA for narsoplimab in TA-TMA; PDUFA date Sep 25, 2025. Phase 3 PNH program paused to conserve cash."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.58,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":797576345.5519421,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":152079,"accession_number":"0001437749-25-014815","cik":1285819,"company_name":"OMEROS CORP","ticker":"OMER","form_type":"8-K","filed_at":"2025-05-06T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Omeros announces FDA accepts BLA resubmission for narsoplimab in TA-TMA; PDUFA late Sept 2025","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA accepted Class 2 resubmission of BLA for narsoplimab for TA-TMA; PDUFA target action date late September 2025.","Resubmission includes survival analyses comparing narsoplimab-treated patients to external control, showing statistically significant improvement.","Also includes data from expanded access program in adult and pediatric TA-TMA patients.","Omeros is preparing MAA for submission to European Medicines Agency later this quarter.","Company responding to FDA information requests; expects interactive review."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":797576345.5519421,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170899,"accession_number":"0001437749-25-010211","cik":1285819,"company_name":"OMEROS CORP","ticker":"OMER","form_type":"8-K","filed_at":"2025-03-31T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Omeros Q4 net loss $31.4M; BLA resubmitted for narsoplimab; PDUFA Sept 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss Q4 2024 $31.4M ($0.54/sh) vs Q3 $32.2M; FY2024 loss $156.8M vs $117.8M prior year.","Cash and investments $90.1M at Dec 31, 2024, down $81.7M from year-end 2023; $42.7M cost outlays.","OMIDRIA royalties Q4 $10.1M on Rayner sales $33.6M, up from $9.3M on $31.0M in Q3.","BLA for narsoplimab in TA-TMA resubmitted to FDA Mar 2025; PDUFA target September 2025.","Phase 3 for zaltenibart in PNH initiated; NIDA awarded $4.02M for OMS527 CUD study; data readout by year-end 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.58,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":797576345.5519421,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170898,"accession_number":"0001437749-25-004505","cik":1285819,"company_name":"OMEROS CORP","ticker":"OMER","form_type":"8-K","filed_at":"2025-02-20T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Omeros reports robust narsoplimab EAP survival data in TA-TMA; BLA resubmission planned Q1 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Combined EAP + pivotal trial vs external control: HR 0.34-0.46, p-values <0.00001 to 0.00002.","Previously untreated high-risk adults: 1-year survival 58%; children: 79% in EAP.","Refractory patients (failed complement inhibitors): 1-year survival 44% vs historical <20%.","No safety signals; BLA resubmission expected later Q1 2025, MAA submission by mid-2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":797576345.5519421,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170897,"accession_number":"0001437749-25-001245","cik":1285819,"company_name":"OMEROS CORP","ticker":"OMER","form_type":"8-K","filed_at":"2025-01-16T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Omeros narsoplimab sensitivity analyses confirm survival benefit; BLA resubmission planned this quarter","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sensitivity analyses show HR 0.24–0.42 vs external control, p-values 0.0124 to <0.00001, confirming primary endpoint robustness.","Primary endpoint (Dec 19): HR=0.32 (95% CI 0.23–0.44), p<0.00001, over 3-fold mortality reduction in TA-TMA patients.","Omeros targets BLA resubmission to FDA later this quarter and European MAA submission by mid-year.","Narsoplimab has been well tolerated across trials with no safety signal of concern."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":797576345.5519421,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":187866,"accession_number":"0001437749-24-037898","cik":1285819,"company_name":"OMEROS CORP","ticker":"OMER","form_type":"8-K","filed_at":"2024-12-19T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Omeros narsoplimab meets TA-TMA pivotal trial primary endpoint; HR 0.32 for survival","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Narsoplimab-treated TA-TMA patients had over 3-fold reduction in risk of death (HR 0.32, 95% CI 0.23-0.44, p<0.00001) vs >100 external control patients.","Omeros will resubmit the narsoplimab BLA to FDA as soon as possible for first approved TA-TMA therapy.","Expanded access program data: 46% of adults and 50% of children achieved TA-TMA resolution after failing C5 inhibitors.","European marketing authorisation application planned for Q2 2025; additional sensitivity analyses and manuscripts expected early 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":797576345.5519421,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":187865,"accession_number":"0001437749-24-034900","cik":1285819,"company_name":"OMEROS CORP","ticker":"OMER","form_type":"8-K","filed_at":"2024-11-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Omeros Q3 net loss $32.2M; narsoplimab BLA resubmission path cleared after FDA meeting","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss Q3 2024: $32.2M ($0.56/sh) vs $37.8M ($0.60/sh) in Q3 2023; nine-month loss $125.5M.","Cash and investments $123.2M at Sept 30, down $48.7M from Dec 31, 2023, including $18.4M narsoplimab drug substance charge and $21.2M debt repurchase.","Narsoplimab in TA-TMA: FDA presubmission in Sep 2024; minor feedback on statistical plan incorporated; BLA resubmission planned after efficacy analysis; European MAA in H1 2025.","Zaltenibart (OMS906): FDA and EU regulators agree on Phase 3 design for PNH; enrollment expected early 2025; rare pediatric disease designation for C3G.","OMIDRIA royalties $9.3M on Rayner’s U.S. sales $31.0M in Q3 2024 vs $10.0M on $33.3M in Q3 2023."],"consensus_eps_estimate":-0.4539,"consensus_eps_actual":-2.15,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":797576345.5519421,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":204389,"accession_number":"0001437749-24-025179","cik":1285819,"company_name":"OMEROS CORP","ticker":"OMER","form_type":"8-K","filed_at":"2024-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Omeros Q2 net loss $56M ($0.97/sh) vs $37M; restructures debt with $67M term loan","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $56.0M ($0.97/sh) vs $37.3M ($0.59); includes $17.6M narsoplimab charge, $21.2M debt repurchase.","Entered $67.1M secured term loan with Athyrium/Highbridge; repurchased $118.1M of 5.25% 2026 notes at ~25% discount.","Cash and investments $158.9M at June 30; OMIDRIA royalties $10.9M on Rayner net sales $36.4M.","FDA meeting scheduled for narsoplimab BLA resubmission in TA-TMA; Phase 3 for zaltenibart in PNH on track for late 2024.","Zaltenibart Phase 2 data: mean hemoglobin improvement 3.27 g/dL; 10/12 patients advanced to monotherapy."],"consensus_eps_estimate":-0.4906,"consensus_eps_actual":-1.6,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":797576345.5519421,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":221153,"accession_number":"0001437749-24-020102","cik":1285819,"company_name":"OMEROS CORP","ticker":"OMER","form_type":"8-K","filed_at":"2024-06-12T23:59:59+00:00","items":["5.02","5.07"],"status":"ready","headline":"Omeros CFO Jacobsen retiring June 30; Borges appointed successor","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Michael A. Jacobsen retires as VP Finance, CAO & Treasurer effective June 30, 2024; stays as part-time advisor at $5k/month.","David J. Borges named VP Finance, CAO & Treasurer effective June 30; base salary $325k, target bonus 35%.","Annual meeting elects directors Bumol, Demopulos, Hood; say-on-pay passes with 15.85M for vs 6.98M against.","Ratification of Ernst & Young as auditor for FY2024 approved by 41.81M votes.","Borges joined Omeros in 2020; prior roles at Merck and Bulletproof 360; CPA."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":797576345.5519421,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":221152,"accession_number":"0001437749-24-018964","cik":1285819,"company_name":"OMEROS CORP","ticker":"OMER","form_type":"8-K","filed_at":"2024-06-03T23:59:59+00:00","items":["1.01","2.03","7.01","8.01","9.01"],"status":"ready","headline":"Omeros enters $92.1M term loan, repurchases $118.1M convertible notes at 74.75% of par, extinguishes $51M debt","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["New $67.1M initial term loan funded June 3, 2024, plus $25M delayed draw available upon FDA approval of narsoplimab for TA-TMA.","Used $67.1M loan and $21.2M cash to repurchase $118.1M (55%) of 5.25% convertible notes due 2026, resulting in $51M debt extinguishment.","Non-dilutive transaction; no equity component. Loans mature June 3, 2028, with interest at SOFR (3% floor) + 8.75% per annum.","Credit agreement requires maintaining ≥$25M unrestricted cash; additional repurchases of 2026 notes permitted under limitations.","After repurchase, $97.9M of 2026 notes outstanding; Omeros retains flexibility to exchange up to $16.9M notes for cash and additional term loans."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":797576345.5519421,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":221151,"accession_number":"0001437749-24-017044","cik":1285819,"company_name":"OMEROS CORP","ticker":"OMER","form_type":"8-K","filed_at":"2024-05-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Omeros Q1 net loss $37.2M; cash extends into 2026 after $115.5M royalty deal","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $37.2M ($0.63/share) vs $33.7M ($0.54) in Q1 2023; loss from cont ops $43.9M vs $39.7M.","Cash + short-term investments $230.3M at Mar 31, up $58.5M from Dec 31; includes $115.5M from DRI royalty deal.","Sold DRI expanded OMIDRIA royalty: DRI gets all US royalties through 2031; Omeros retains ex-US & post-2031 global; potential milestones up to $27.5M each.","OMS906 Phase 2 PNH data at EHA June 15; Phase 3 start late 2024. Narsoplimab BLA resubmission timeline uncertain pending FDA.","Repurchased 3.2M shares for $11.9M in Q1."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.63,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":797576345.5519421,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":221150,"accession_number":"0001437749-24-010359","cik":1285819,"company_name":"OMEROS CORP","ticker":"OMER","form_type":"8-K","filed_at":"2024-04-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Omeros posts Q4 net loss $9.1M, secures $115.5M from OMIDRIA royalty sale","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2023 net loss $9.1M ($0.15/sh) vs Q3 loss $37.8M; full-year net loss $117.8M ($1.88/sh) vs prior-year net income $47.4M.","Amended OMIDRIA royalty deal with DRI: received $115.5M; DRI gets all U.S. royalties through 2031; Omeros retains ex-U.S. & post-2031 global royalties; potential $55M milestones.","Cash and investments $171.8M at Dec 31, 2023; plus $115.5M from DRI in Feb 2024; expects ~$230M at Mar 31, 2024 after share repurchases.","Narsoplimab BLA resubmission in TA-TMA still under FDA discussion; unable to estimate timing for submission or approval.","OMS906 Phase 2 trials in PNH fully enrolled; positive interim data; Phase 3 targeted late 2024; OMS1029 Phase 1 multiple-ascending dose completed."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.63,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":797576345.5519421,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}